Global Pharmaceutical Stability & Storage Services Market Size Likely to Expand at a CAGR of 5.3% By 2033

As per the current market research conducted by the CMI Team, the global Pharmaceutical Stability & Storage Services Market size is expected to record a CAGR of 5.3% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 1.8 billion. By 2032, the valuation is anticipated to reach USD 3.2 billion.

Pharmaceutical Stability & Storage Services Market: Growth Factors and Dynamics

• Regulatory Compliance and Quality Assurance: The pharmaceutical industry is highly regulated, and maintaining product stability is crucial to ensure drug efficacy and safety. Pharmaceutical stability services play a vital role in helping companies comply with regulatory guidelines and quality assurance standards, driving the demand for these services.

• Globalization of Pharmaceutical Supply Chain: The pharmaceutical supply chain has become more globalized, with companies often sourcing raw materials, manufacturing, and distributing drugs across different regions. This trend increases the need for stability testing services to ensure that products remain stable under varying climatic and transportation conditions.

• Rise in Biopharmaceuticals and Biologics: The growth of biopharmaceuticals and biologics has been significant in recent years. These complex molecules require specialized stability testing due to their sensitivity to factors like temperature, light, and pH. This drives the demand for tailored stability testing services.

• Patent Expirations and Generic Drug Development: As patents for many blockbuster drugs expire, the generic drug market expands. Generic manufacturers require stability testing to demonstrate the equivalence of their products to the innovator drugs. This contributes to the growth of stability testing services.

• Complex Drug Formulations: Pharmaceuticals are increasingly developed with intricate formulations, including controlled-release dosage forms, combination products, and nanomedicines. The stability of these formulations is critical to ensure consistent drug delivery, prompting the need for specialized stability testing.

• Technological Advancements: Advances in analytical techniques, automation, and data analysis have improved the efficiency and accuracy of stability testing. This allows pharmaceutical companies to monitor and predict product stability more effectively, facilitating early intervention and decision-making.

• Increasing Focus on Personalized Medicine: The shift towards personalized medicine, where treatments are tailored to individual patient’s needs, requires precise formulation and stability testing. As pharmaceutical companies develop personalized therapies, the demand for stability services that ensure the stability and efficacy of these customized treatments is expected to rise.

Pharmaceutical Stability & Storage Services Market: Partnership and Acquisitions

• Pfizer and Parexel: In 2020, Pfizer signed a new three-year deal with contract research organization Parexel, adding to its decade-long collab. Parexel will provide Pfizer clinical development services via full-service, hybrid and functional service provider (FSP) models across all therapeutic areas, including rare diseases, oncology, inflammation and immunology and internal and hospital-based medicines.

• Good Reasons to Partnership with Eurofins: In 2023, Good Reasons to Partnership with Eurofins. With over 38,000 staff in more than 400 laboratories across 44 countries and more than 30 laboratories in personal care, our laboratories provide a unique range of analytical testing services to the pharmaceutical, food, environmental, consumer products industries and governments.

Report Scope

Pharmaceutical Stability & Storage Services Market: COVID-19 Analysis

The COVID-19 pandemic has had a significant impact on the Pharmaceutical Stability & Storage Services Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• Disruption in Supply Chains and Operations: The COVID-19 pandemic led to disruptions in global supply chains, including the pharmaceutical industry. Lockdowns, travel restrictions, and reduced workforce availability impacted the transportation of samples and materials needed for stability testing. This disrupted operations, delayed testing timelines, and affected the availability of stability data for regulatory submissions.

• Focus on Essential Drugs and Clinical Trials: During the pandemic, the pharmaceutical industry experienced a shift in priorities towards the development and production of essential drugs, including vaccines and treatments for COVID-19. This diverted resources away from non-COVID-related stability testing, leading to delayed or postponed projects in other therapeutic areas.

• Resumed R&D Activities: As the pandemic situation improves and restrictions are lifted, pharmaceutical companies will resume and accelerate their research and development activities. This will lead to an increased demand for stability testing services as companies work to catch up on delayed projects and advance new drug candidates.

• Emphasis on Supply Chain Resilience: The disruptions caused by COVID-19 highlighted the need for more resilient supply chains in the pharmaceutical industry. Companies may invest in strategies to diversify suppliers, optimize transportation, and secure backup plans, which could lead to an increased requirement for stability testing to ensure products remain viable throughout the supply chain.

• Increased Regulatory Scrutiny: Regulatory agencies understand the impact of the pandemic on drug development timelines. However, they will likely maintain rigorous quality and safety standards. This could lead to intensified regulatory scrutiny on stability data and testing, driving companies to ensure their products meet all necessary requirements.

• Integration of Digital Solutions: The pandemic accelerated the adoption of digital and remote solutions across industries. In the Pharmaceutical Stability & Storage Services Market, this could lead to the implementation of advanced digital monitoring systems that allow real-time tracking of stability conditions and reduce the need for physical presence.

In conclusion, the COVID-19 pandemic has had a mixed impact on the Pharmaceutical Stability & Storage Services Market, with some challenges and opportunities arising from the pandemic.

List of the prominent players in the Pharmaceutical Stability & Storage Services Market:

• Eurofins Scientific SE
• Almac Group
• Charles River Laboratories International Inc.
• Intertek Group plc
• SGS SA
• Pace Analytical Services LLC
• IQVIA (formerly QuintilesIMS)
• Eurofins Lancaster Laboratories
• Element Materials Technology (formerly Exova Group)
• Boston Analytical Inc.
• Others

The Pharmaceutical Stability & Storage Services Market is segmented as follows:

By Service

• Stability
  • Drug Substance
  • Stability indicating method validation.
  • Accelerated stability testing.
  • Photostability Testing
  • Other stability testing methods
• Storage
  • Cold
  • Non-cold
• Consulting and Regulatory Support
• Others

By Molecule

• Large Molecule
• Small Molecule

By Mode

• In-house
• Outsourcing

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America